Prion Diseases
Prion diseases are lethal neurodegenerative conditions triggered by aberrantly folded prion proteins (PrPSc). Protheragen is dedicated to delivering advanced diagnostic and therapeutic development solutions that meet every challenge posed by prion disease management. We offer an integrated suite of high-quality services tailored to advanced your scientific research from early-stage validation through to preclinical preparedness.
Introduction to Prion Diseases
Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), form a distinct group of relentlessly progressive neurodegenerative conditions that are transmissible solely via their abnormal protein conformation. The diseases, which manifest in both humans and a variety of animal species, are distinguished by the progressive spongiform change, the selective loss of neurons, and the accumulation of misfolded prion protein (PrPSc). Several common prion diseases are listed below.
| Disease | Etiology | Clinical Presentation | Incidence |
| Sporadic Creutzfeldt-Jakob disease (sCJD) | Spontaneous PrPSc conversion | Rapid dementia, myoclonus, akinetic mutism | 1-2 cases/million |
| Fatal Familial Insomnia (FFI) | Autosomal dominant PRNP mutation (D178N) | Progressive insomnia, autonomic dysfunction | Extremely rare |
| Gerstmann-Sträussler-Scheinker (GSS) | Autosomal dominant PRNP mutation (P102L) | Cerebellar ataxia, dysarthria | ~1-10 cases/100 million |
| Variant Creutzfeldt-Jakob disease (vCJD) | Acquired (BSE prion exposure) | Early psychiatric symptoms, sensory changes | ~232 cases worldwide |
Pathogenesis of Prion Diseases
The pathogenesis of prion diseases centers on the conformational conversion of normal cellular prion protein (PrPC) into its pathogenic isoform (PrPSc), which propagates through self-templating and accumulates as neurotoxic aggregates. This misfolding triggers synaptic dysfunction, proteostasis failure, and neuronal death, with disease presentation (sporadic, genetic, or acquired) determined by PrPSc strain properties and host factors like PRNP mutations or codon 129 polymorphism (MM/MV/VV).
Fig.1 Microglial response in healthy versus prion disease conditions in the brain. (Assis-de-Lemos G, et al., 2024)
Therapeutic Development for Prion Diseases
| Drug Names | Mechanism of Action | Targets | NCT Number | Research Phase |
| ION717 | Antisense oligonucleotide reducing PRNP mRNA expression | PRNP gene | NCT06153966 | Phase I/II |
| Quinacrine | >Binds PrPSc to inhibit fibril formation and promote clearance | >Misfolded PrPSc aggregates | NCT00104663 | Phase II |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
At Protheragen, we drive preclinical research into prion diseases, offering end-to-end support that spans from biomarker discovery straight through to CNS-targeted therapeutic candidates. Leveraging our proficiency in disease modeling, we deploy patient-derived iPSCs, genetically engineered models, and cutting-edge blood-brain barrier (BBB) models to assess both compound penetration and neuroprotection.
Therapeutic Development Services
By Mechanism of Action
Disease Model Development Services
In Vitro Model Development
- Prnp Knockout Model: Mice completely lacking the PrP protein, used to validate PrP-dependent pathogenesis.
- Prnp Transgenic Model: Mice expressing exogenous PRNP genes, enabling species-specific prion replication studies.
To advance the commercialization of novel therapies for priondiseases, Protheragen provides comprehensive preclinical research services, coveringpharmacodynamics (PD), pharmacokinetics (PK), and toxicology studies. If you areinterested in our services, please feel free to contact us for more detailsand quotation information of related services.
Reference
- Assis-de-Lemos G, Moura-do-Nascimento R, Amaral-do-Nascimento M, etal. Interactions between Cytokines and the Pathogenesis of Prion Diseases:Insights and Implications[J]. Brain Sciences, 2024, 14(5): 413.